Top

Published in:

01-07-2009 | Original Article—Alimentary Tract

The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy

Authors: Akiko Shiotani, Takashi Sakakibara, Yoshiyuki Yamanaka, Ryuji Nishi, Hiroshi Imamura, Minoru Fujita, Ken-ichi Tarumi, Tomoari Kamada, Jiro Hata, Ken Haruma

Published in: Journal of Gastroenterology | Issue 7/2009

Abstract

Purpose

Interleukin-1β (IL-1β) polymorphisms are associated with peptic ulcer and atrophic gastritis. This study aimed to examine effects of corpus atrophy and the genotypes of genes related to peptic ulcer, including IL-1β, on risk of aspirin ulcer.

Methods

232 patients taking 100 mg of aspirin for cardiovascular diseases, of whom 40 had peptic ulcer, were enrolled. IL1β, interleukin-1 receptor antagonist (IL-1RN), tumor necrosis factor (TNF)-α, cyclooxygenase (COX)-1, cytochrome p450 2C9 (CYP2C9), UDP-glucuronosyltransferase (UGT1A6) genotypes were determined, and serum pepsinogen levels were measured.

Results

The polymorphisms of IL-1β-511/-31 were significantly associated with peptic ulcer, but other genotypes were not. Serum pepsinogen I and II levels and I/II ratio were significantly higher in the ulcer group than in the non-ulcer group. Taking PPI [adjusted odds ratio (OR), 0.09; 95% confidence interval (CI), 0.02–0.39], pepsinogen I of less than 50 ng/ml (OR, 0.24; 95% CI, 0.10–0.56) and IL-1β-511 T carrier (OR, 0.42; 95% CI, 0.18–0.93) were significantly associated with peptic ulcer.

Conclusions

Hypoacidity related to corpus atrophy as well as taking PPI seems to be preventively associated with development of peptic ulcer among low dose aspirin users.

Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206–18.PubMed

Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther. 2003;73:122–30.PubMedCrossRef

Lampe JW, Bigler J, Horner NK, Potter JD. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics. 1999;9:341–9.PubMedCrossRef

Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 2001;61:3566–9.PubMed

Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology. 1999;117:17–25.PubMedCrossRef

Kitahora T, Guth PH. Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation. Gastroenterology. 1987;93:810–7.PubMed

Sato Y, Asaka M, Takeda H, Ohtaki T, Miyazaki T. The mechanisms of aspirin-induced gastric mucosal injury. J Clin Gastroenterol. 1993;17(Suppl 1):S1–4.PubMed

Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343:834–9.PubMedCrossRef

Lanas A, Garcia-Rodriguez LA, Arroyo MT, Bujanda L, Gomollon F, Forne M, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102:507–15.PubMedCrossRef

10.

Sakamoto C, Sugano K, Ota S, Sakaki N, Takahashi S, Yoshida Y, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol. 2006;62:765–72.PubMedCrossRef

11.

Shiotani A, Sakakibara T, Yamanaka Y, Imamura H, Tarumi K, Manabe N, et al. Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin. J Gastroenterol. 2009;44:126–31.PubMedCrossRef

12.

Shiotani A, Kamada T, Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol. 2008;43:581–8.PubMedCrossRef

13.

Shiotani A, Yamaoka Y, El-Zimaity HM, Saeed MA, Qureshi WA, Graham DY. NSAID gastric ulceration: predictive value of gastric pH, mucosal density of polymorphonuclear leukocytes, or levels of IL-8 or nitrite. Dig Dis Sci. 2002;47:38–43.PubMedCrossRef

14.

Garcia-Gonzalez MA, Savelkoul PH, Benito R, Santolaria S, Crusius JB, Pena AS, et al. No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. Int J Immunogenet. 2005;32:299–306.PubMedCrossRef

15.

Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology. 2002;123:92–105.PubMedCrossRef

16.

Zambon CF, Basso D, Navaglia F, Belluco C, Falda A, Fogar P, et al. Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine. 2005;29:141–52.PubMedCrossRef

17.

Sugimoto M, Furuta T, Shirai N, Nakamura A, Xiao F, Kajimura M, et al. Different effects of polymorphisms of tumor necrosis factor-alpha and interleukin-1 beta on development of peptic ulcer and gastric cancer. J Gastroenterol Hepatol. 2007;22:51–9.PubMedCrossRef

18.

Garcia-Gonzalez MA, Lanas A, Santolaria S, Crusius JB, Serrano MT, Pena AS. The polymorphic IL-1B and IL-1RN genes in the aetiopathogenesis of peptic ulcer. Clin Exp Immunol. 2001;125:368–75.PubMedCrossRef

19.

El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404:398–402.PubMedCrossRef

20.

van Oijen MG, Huybers S, Peters WH, Drenth JP, Laheij RJ, Verheugt FW, et al. Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid. Br J Clin Pharmacol. 2005;60:623–8.PubMed

21.

van Oijen MG, Laheij RJ, Koetsier M, de Kleine E, Te Morsche RH, van Kerkhoven LA, et al. Effect of a specific cyclooxygenase-gene polymorphism (A-842G/C50T) on the occurrence of peptic ulcer hemorrhage. Dig Dis Sci. 2006;51:2348–52.PubMedCrossRef

22.

Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Sugimura H, et al. Effects of interleukin-10 gene polymorphism on the development of gastric cancer and peptic ulcer in Japanese subjects. J Gastroenterol Hepatol. 2007;22:1443–9.PubMedCrossRef

23.

Saeki M, Saito Y, Jinno H, Sai K, Kaniwa N, Ozawa S, et al. Genetic polymorphisms of UGT1A6 in a Japanese population. Drug Metab Pharmacokinet. 2005;20:85–90.PubMedCrossRef

24.

Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, et al. Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan. Int J Mol Med. 2007;20:373–8.PubMed

25.

Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007;133:465–71.PubMedCrossRef

26.

Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004;141:205–8.PubMedCrossRef

27.

Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther. 1998;63:519–28.PubMedCrossRef

28.

Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001;40:587–603.PubMedCrossRef

29.

Samloff IM, Secrist DM, Passaro E Jr. A study of the relationship between serum group I pepsinogen levels and gastric acid secretion. Gastroenterology. 1975;69:1196–200.PubMed

30.

Samloff IM, Kleinman MS. A radial diffusion assay for pepsinogen and pepsin. Gastroenterology. 1969;56:30–4.PubMed

31.

Nomura AM, Stemmermann GN, Samloff IM. Serum pepsinogen I as a predictor of stomach cancer. Ann Intern Med. 1980;93:537–40.PubMed

32.

Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, Miyazaki T, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102:760–6.PubMed

33.

Shiotani A, Nishioka S, Iguchi M, Yanaoka K, Okada K, Tamai H, et al. Duodenal erosions after eradication of Helicobacter pylori infection. Gastrointest Endosc. 2001;54:448–53.PubMedCrossRef

34.

Kikuchi S, Wada O, Miki K, Nakajima T, Nishi T, Kobayashi O, et al. Serum pepsinogen as a new marker for gastric carcinoma among young adults. Research Group on Prevention of Gastric Carcinoma among Young Adults. Cancer. 1994;73:2695–702.PubMedCrossRef

35.

Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut. 1999;44:693–7.PubMedCrossRef

36.

Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, et al. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand J Gastroenterol. 2000;35:950–6.PubMedCrossRef

37.

Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol. 2003;98:735–9.PubMedCrossRef

Title: The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy
Authors: Akiko Shiotani
Takashi Sakakibara
Yoshiyuki Yamanaka
Ryuji Nishi
Hiroshi Imamura
Minoru Fujita
Ken-ichi Tarumi
Tomoari Kamada
Jiro Hata
Ken Haruma
Publication date: 01-07-2009
Publisher: Springer Japan
Published in: Journal of Gastroenterology / Issue 7/2009
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-009-0068-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2009

The loss of HBeAg without precore mutation results in lower HBV DNA levels and ALT levels in chronic hepatitis B virus infection

Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a North Indian population

Acid and non-acid reflux in Japanese patients with non-erosive reflux disease with persistent reflux symptoms, despite taking a double-dose of proton pump inhibitor: a study using combined pH-impedance monitoring

Comparison of gastroesophageal reflux in 100 patients with or without prior gastroesophageal surgery

Prevalence of ulcerative colitis and Crohn’s disease in Japan

Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials